The new oral cephalosporins in community-acquired infections

Clinical Microbiology and Infection

Volumn 6, Issue S3, 2000, Pages 64-69

  Low, D E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CELLULITIS; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG INDICATION; FOLLOW UP; HOSPITAL COST; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OTITIS MEDIA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCAL PHARYNGITIS; TONSILLITIS; TREATMENT DURATION; COMMUNICABLE DISEASE; GONORRHEA; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PNEUMONIA; REVIEW;

ADMINISTRATION, ORAL; CELLULITIS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; GONORRHEA; HUMANS; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; TONSILLITIS;

EID: 17944371374     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2000.tb02047.x     Document Type: Article

References (43)

1. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever. Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics 1995; 96: 758-64.
2. Feldman S, Bisno AL, Lott L, Dodge R, Jackson RE. Efficacy of benzathine penicillin G in group A streptococcal pharyngitis: reevaluation. J Pediatr 1987; 110: 783-7.
3. Gastanaduy AS, Kaplan EL, Huwe BB, McKay C, Wannamaker LW. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980; ii: 498-502.
4. Stillerman M. Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis. Pediatr Infect Dis 1986; 5: 649-54.
5. Portier H, Chavanet P, Waldner-Combernoux A et al. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis 1994; 26: 59-66.
6. Pichichero ME, Gooch WM, Rodriguez W et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148: 1053-60.
7. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991; 10: 275-81.
8. Holm S, Henning C, Grahn E, et al. Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Scand J Infect Dis 1995; 27: 221-8.
9. Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13: 1-7.
10. Reichler MR, Allphin AA, Breiman RF et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992; 166: 1346-53.
11. Kristinsson KG, Hjalmarsdottir MA, Steingrinisson O. Increasing penicillin resistance in pneumococci in Iceland, Lancet 1992; 339: 1606-7.
12. Munoz R, Coffey TJ, Daniels M et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-6.
13. Stephenson J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA 1996; 275: 175.
14. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
15. Appelbaum PC. Antibiotic-resistant pneumococci - facts and fiction. J Chemother 1994; 6 (Suppl. 4): 7-15.
16. Paradise JL. Treatment guidelines for otitis media: the need for breadth and flexibility. Pediatr Infect Dis J 1995; 14: 429-35.
17. Bryskier A, Belfiglio SR. Cephalosporins: Oral. In: Yu VL, Merigan TC, ed. Antimicrobial Therapy and Vaccines. Baltimore, Maryland: Barriere Williams and Wilkens. 1998: 703-48.
18. Dagan R, Abramson O, Leibovitz F et al.. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15: 980-5.
19. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998; 42: 589-95.
20. van Dyk JC, Terespolsky SA, Meyer CS, van Niekerk CH, Klugman KP. Penetration of cefpodoxime into middle ear fluid in pediatric patients with acute otitis media. Pediatr Infect Dis J 1997; 16: 79-81.
21. Gehanno P, Barry B, Bobin S, Safran C. Twice daily cefpodoxime proxetil compared with thrice daily amoxicillin/clavulanic acid for treatment of acute otitis media in children. Scand J Infect Dis 1994; 26: 577-84.
22. Richard MP, Aguado AG, Mattina R, Marre R. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance. J Antimicrob Chemother 1998; 41: 207-14.
23. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SE et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998; 279: 1736-42.
24. Cohen R, Levy C, Boucherat M, Langue J, de La Rocque F. A multicenter, randomized, double-blind trial of 5 versus 10 days of antibiotic therapy for acute otitis media in young children. J Pediatr 1998; 133: 634-9.
25. Fang GD, Fine M, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307-16.
26. Wallace RJJ, Musher DM, Septimus EJ et al. Haemophilus influenzae infections in adults: characterization of strains by serotypes, biotypes, and beta-lactamase production. J Infect Dis 1981; 144: 101-6.
27. Deulofeu F, Nava JM, Bella F et al. Prospective epidemiological study of invasive Haemophilus influenzae disease in adults. Eur J Clin Microbiol Infect Dis 1994; 13: 633-8.
28. Petrof EO, Low DE. Canadian Bacterial Surveillance Network et al. Serotype characterization of Haemophilus influenzae isolates causing invasive disease in Canada following the introduction of Hib vaccines. Abstracts of 16th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1996.
29. Anonymous. Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1997; 99: 289-99.
30. Klugman KP. Epidemiology, control and treatment of multiresistant pneumococci. Drugs 1996; 52 (Suppl. 2): 42-6.
31. Goldstein FW, Garau J. 30 years of penicillin-resistant S pneumoniae: myth or reality? Lancet 1997; 350: 233-4.
32. Strachan SA, Friedland IR. Therapy for penicillin-resistant Streptococcus pneumoniae. J Med Microbiol 1995; 43: 237-8.
33. Goldstein FW. Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scand J Infect Dis 1997; 29: 255-7.
34. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 213-7.
35. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
36. Appelbaum PC. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microb Drug Resist 1995; 1: 43-8.
37. Wise R. The pharmacokinetics of the oral cephalosporins-a review. J Antimicrob Chemother 1990; 26 (Suppl. E): 13-20.
38. Chong LY, Cheung WM, Leung CS, Yu CW, Chan LY. Clinical evaluation of cefubuten in gonorrhea. A pilot study in Hong Kong. Sex Transm Dis 1998; 25: 464-7.
39. Knapp JS. Neisseria gonorrhoeae resistant to ciprofloxacin and ofloxacin. Sex Transm Dis 1998; 25: 425-6.
40. Hamilton-Miller J. Cefixime for switch therapy. Chemotherapy 1998; 44 (Suppl. 1): 24-7.
41. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-6.
42. Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, cembuten, loracarbef, cefprozil. BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection 1991; 19: 353-62.
43. Felmingham D, Robbins MJ, Ghosh G et al. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res 1994; 20: 127-47.